Skip to content

Parathyroid Adenoma Detection With Rubidium-82 Imaging

Parathyroid Adenoma Detection With Rubidium Chloride Imaging: A Proof-of-Concept Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07099404
Acronym
PARAGON
Enrollment
20
Registered
2025-08-01
Start date
2025-11-30
Completion date
2028-09-30
Last updated
2025-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperparathyroidism, Primary, Parathyroid Adenomas

Keywords

Parathyroid adenomas, Rubidium-82

Brief summary

Assess the uptake of rubidium-82 in parathyroid adenomas.

Detailed description

Parathyroid adenomas demonstrate uptake of rubidium-82 chloride and can be detected with PET imaging. The investigators aim to describe the uptake pattern of rubidium-82 chloride in parathyroid adenomas as well as compare the uptake pattern of rubidium-82 chloride to that of 18F-fluorocholine in patients with parathyroid adenoma.

Interventions

OTHERPET/CT imaging with rubidium-82

PET imaging of the neck will be started immediately before infusion of 10 Megabecquerels per kilograms of rubidum-82 over 30 seconds. The acquisition will last 10 minutes. This will be followed by a non-contrast low-dose CT of the neck for localization and attenuation correction.

Sponsors

Matthieu Pelletier-Galarneau, MD MSc
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age ≥ 18y 2. Ability to undergo imaging logistics 3. Ability to provide informed consent 4. Biochemical evidence of primary hyperparathyroidism 5. Documented parathyroid adenoma on prior 18F-fluorocholine imaging

Exclusion criteria

1. Normocalcemic primary hyperparathyroidism 2. Breastfeeding or pregnancy 3. Claustrophobia or inability to undergo imaging logistics 4. Any other history, condition, therapy, or uncontrolled intercurrent illness, which could in the opinion of the investigator affect compliance with study requirements or which would make the participant unsuitable for this study

Design outcomes

Primary

MeasureTime frameDescription
Uptake pattern of rubidium-82 in parathyroid adenomas3 monthsRudibium-82 uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.

Secondary

MeasureTime frameDescription
Comparison between the uptakes of rubidium-82 and 18F-fluorocholine in patients with parathyroid adenomas3 monthsRadioactive tracer uptake will be compared between Rudibium-82 and 18F-Fluorocholine. Uptake will be assessed using Maximum Standardized Uptake Value (SUVmax) and target-to-background ratios (TBR). TBR is calculated by dividing a lesion SUVmax by the mean SUV (SUVmean) or the blood pool. Maximum Standardized Uptake Value (SUVmax) and target-to-background (TBR) will be presented as median with interquartile range as well as minimum and maximum values.

Countries

Canada

Contacts

Primary ContactMatthieu Pelletier-Galarneau, MD MSc
matthieu.pelletier-galarneau@icm-mhi.org514-376-3330
Backup ContactPelletier-Galarneau

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026